CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Vasopressin

加压素 杂质对照品Vasopressin Impurities

15 个杂质条目15 impurity entries

本页汇总 加压素 的 15 个杂质对照品条目。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 15 impurity reference standards of Vasopressin. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 加压素(Vasopressin)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesImpurity identification and quantification for arginine vasopressin by liquid chromatography/high-resolution mass spectrometry
    Rapid communications in mass spectrometry : RCM · 2020 · Wu P et al.  ·  PMID 32247289  ·  DOI
  2. 杂质研究Impurity studiesExtended stability of vasopressin 0.2 unit/mL in PVC containers
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2023 · Bae H et al.  ·  PMID 36272113  ·  DOI
  3. 分析方法Analytical MethodsQuantification of receptor activation by oxytocin and vasopressin in endocytosis-coupled bioluminescence reduction assay using nanoKAZ
    Analytical biochemistry · 2018 · Kii I et al.  ·  PMID 29627593  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisIdentification and synthesis of major metabolites of Vasopressin V2-receptor agonist WAY-151932, and antagonist, Lixivaptan
    Bioorganic & medicinal chemistry letters · 2007 · Molinari AJ et al.  ·  PMID 17855087  ·  DOI
  • 合成方法SynthesisMelatonin and the synthesis of vasopressin in pinealectomized male rats
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) · 2000 · Juszczak M et al.  ·  PMID 11082215  ·  DOI

加压素 —— 原料药与杂质对照品Vasopressin — drug substance & impurities

共 16 个条目(含原料药本体)16 items incl. the drug substance
Vasopressin structure
原料药 APIAPI
加压素Vasopressin
Vasopressin
CAS No.11000-17-2
Chemical FormulaC46H65N15O12S2
Purity>95%询价On request
10mg25mg50mg100mg
Vasopressin Impurity 1 (Endo-Gly10 Vasopressin ) structure
1
加压素杂质1(Endo-甘氨酸10 加压素)Vasopressin Impurity 1 (Endo-Gly10 Vasopressin )
Vasopressin Impurity 1 (Endo-Gly10 Vasopressin )
CAS No.77403-94-2
Chemical FormulaC48H68N16O13S2
Purity>95%询价On request
10mg25mg50mg100mg
Vasopressin Impurity 2 (Des Gly Vasopressin) structure
2
加压素杂质2(去甘氨酸 加压素)Vasopressin Impurity 2 (Des Gly Vasopressin)
Vasopressin Impurity 2 (Des Gly Vasopressin)
CAS No.47914-57-8
Chemical FormulaC44H62N14O11S2
Purity>95%询价On request
10mg25mg50mg100mg
Vasopressin Impurity 3 (N-Acetyl Vasopressin) structure
3
加压素杂质3(N-乙酰基加压素)Vasopressin Impurity 3 (N-Acetyl Vasopressin)
Vasopressin Impurity 3 (N-Acetyl Vasopressin)
CAS No.38106-69-3
Chemical FormulaC48H67N15O13S2
Purity>95%询价On request
10mg25mg50mg100mg
Vasopressin Impurity 4 (Des Pro Vasopressin) structure
4
加压素杂质4 (去脯氨酸 加压素)Vasopressin Impurity 4 (Des Pro Vasopressin)
Vasopressin Impurity 4 (Des Pro Vasopressin)
CAS No.119802-36-7
Chemical FormulaC41H58N14O11S2
Purity>95%询价On request
10mg25mg50mg100mg
Vasopressin Impurity 6 (D Gln4 Vasopressin) structure
6
加压素杂质6 (D 谷氨酰胺4 加压素)Vasopressin Impurity 6 (D Gln4 Vasopressin)
Vasopressin Impurity 6 (D Gln4 Vasopressin)
CAS No.76023-59-1
Chemical FormulaC46H65N15O12S2
Purity>95%询价On request
10mg25mg50mg100mg
Vasopressin Impurity 7 structure
7
加压素杂质7Vasopressin Impurity 7
Vasopressin Impurity 7
CAS No.189241-28-9
Chemical FormulaC46H65N15O12S3
Purity>95%询价On request
10mg25mg50mg100mg
Vasopressin Impurity 10 (Glu4 Vasopressin) structure
10
加压素杂质10 (谷氨酸4 加压素)Vasopressin Impurity 10 (Glu4 Vasopressin)
Vasopressin Impurity 10 (Glu4 Vasopressin)
CAS No.2075712-12-6
Chemical FormulaC46H64N14O13S2
Purity>95%询价On request
10mg25mg50mg100mg
Vasopressin Impurity 11 structure
11
加压素杂质11Vasopressin Impurity 11
Vasopressin Impurity 11
CAS No.2075715-46-5
Chemical FormulaC46H65N15O12S2
Purity>95%询价On request
10mg25mg50mg100mg
Vasopressin Impurity 12 (Endo-Gly9a Vasopressin) structure
12
加压素杂质12(Endo-甘氨酸9a 加压素)Vasopressin Impurity 12 (Endo-Gly9a Vasopressin)
Vasopressin Impurity 12 (Endo-Gly9a Vasopressin)
CAS No.114665-05-3
Chemical FormulaC48H67N15O14S2
Purity>95%询价On request
10mg25mg50mg100mg
Vasopressin Impurity 13 (Asp5 Vasopressin) structure
13
加压素杂质13 (天冬氨酸5 加压素)Vasopressin Impurity 13 (Asp5 Vasopressin)
Vasopressin Impurity 13 (Asp5 Vasopressin)
CAS No.78031-79-5
Chemical FormulaC46H64N14O13S2
Purity>95%询价On request
10mg25mg50mg100mg
Vasopressin Impurity 16 (Des Gly9 NH2 Vasopressin) structure
16
加压素杂质16 (去甘氨酸9 氨基 加压素)Vasopressin Impurity 16 (Des Gly9 NH2 Vasopressin)
Vasopressin Impurity 16 (Des Gly9 NH2 Vasopressin)
CAS No.37552-33-3
Chemical FormulaC44H61N13O12S2
Purity>95%询价On request
10mg25mg50mg100mg
Vasopressin Impurity 17 (D Tyr Vasopressin) structure
17
加压素杂质17 (D 酪氨酸 加压素)Vasopressin Impurity 17 (D Tyr Vasopressin)
Vasopressin Impurity 17 (D Tyr Vasopressin)
CAS No.66513-06-2
Chemical FormulaC46H65N15O12S2
Purity>95%询价On request
10mg25mg50mg100mg
Vasopressin Impurity 23 (D Phe3 Vasopressin) structure
23
加压素杂质23 (D 苯丙氨酸3 加压素)Vasopressin Impurity 23 (D Phe3 Vasopressin)
Vasopressin Impurity 23 (D Phe3 Vasopressin)
CAS No.89576-32-9
Chemical FormulaC46H65N15O12S2
Purity>95%询价On request
10mg25mg50mg100mg
Vasopressin Impurity 24 (D Cys6 Vasopressin) structure
24
加压素杂质24 (D 半胱氨酸6 加压素)Vasopressin Impurity 24 (D Cys6 Vasopressin)
Vasopressin Impurity 24 (D Cys6 Vasopressin)
CAS No.163659-75-4
Chemical FormulaC46H65N15O12S2
Purity>95%询价On request
10mg25mg50mg100mg
Vasopressin Impurity 26 (D Cys1 Vasopressin) structure
26
加压素杂质26 (D 半胱氨酸1 加压素)Vasopressin Impurity 26 (D Cys1 Vasopressin)
Vasopressin Impurity 26 (D Cys1 Vasopressin)
CAS No.66513-07-3
Chemical FormulaC46H65N15O12S2
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

加压素 —— 研究文献与合成路线Vasopressin — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 加压素 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Vasopressin. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. ER-associated degradation is required for vasopressin prohormone processing and systemic water homeostasis
    Shi G, Somlo DRM, Kim GH, et al. · The Journal of clinical investigation · 2017 · 被引 90cited 90
  2. Derlin-1 and p97/valosin-containing protein mediate the endoplasmic reticulum-associated degradation of human V2 vasopressin receptors
    Schwieger I, Lautz K, Krause E, et al. · Molecular pharmacology · 2008 · 被引 24cited 24
  3. Downregulation of the vasopressin type 2 receptor after vasopressin-induced internalization: involvement of a lysosomal degradation pathway
    Bouley R, Lin HY, Raychowdhury MK, et al. · American journal of physiology. Cell physiology · 2005 · 被引 43cited 43
  4. Degradation of wild-type vasopressin precursor and pathogenic mutants by the proteasome
    Friberg MA, Spiess M, Rutishauser J · The Journal of biological chemistry · 2004 · 被引 26cited 26
  5. Regulation of V2 vasopressin receptor degradation by agonist-promoted ubiquitination
    Martin NP, Lefkowitz RJ, Shenoy SK · The Journal of biological chemistry · 2003 · 被引 102cited 102
  6. Alix (AIP1) is a vasopressin receptor (V2R)-interacting protein that increases lysosomal degradation of the V2R
    Yi X, Bouley R, Lin HY, et al. · American journal of physiology. Renal physiology · 2007 · 被引 19cited 19

合成与制备工艺专利Synthesis & process patents

  1. 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY AS SELECTIVE LIGANDS OF V2 VASOPRESSIN RECEPTORS
    FOULON LOIC, ROCHARD PIERRICK, SERRADEIL-LE GAL CLAUDINE, VALETTE GERARD · 公开号 EP2097374EP2097374 · 2009
  2. APPLICATION OF ANTAGONISTS OF OXYTOCIN OR ANTAGONISTS OF OXITOCIN AND VASOPRESSIN IN THE MANUFACTURE OF MEDICINES USED IN PROCEDURES OF AIDED REPRODUCTION
    KUCZYNSKI WALDEMAR, PIERZYNSKI PIOTR · 公开号 PL374954PL374954 · 2006
  3. Use of a vasopressin antagonist such as conivaptan in the manufacture of a medicament for treating pulmonary hypertension
    Ghazzi Maha Pfizer Global Research & Development, Pressler Milton Lethan Pfizer Global R&D · 公开号 EP1195166EP1195166 · 2002
  4. BENZO[E][1,4]DIAZEPINE DERIVATIVES CONDENSED WITH BRIDGED BICYCLE, THEIR PREPARATION AND THEIR USE AS VASOPRESSIN RECEPTOR ANTAGONISTS
    DYATKIN ALEXEY B, HOEKSTRA WILLIAM J, MARYANOFF BRUCE E · 公开号 HU0401722HU0401722 · 2005
  5. PROCESS FOR MANUFACTURE OF 1-DEAMINO-8-D-ARGININE VASOPRESSIN
    LARSSON Bo Ake Krister, MELLBRAND Thomas Björn, MÖRNSTAM Ewa Maria Birgitta, ROSCHESTER Jan Anders Ingemar, et al. · 公开号 EP0710247EP0710247 · 1996

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

加压素 杂质谱研究要点Vasopressin — impurity profiling notes

下面这些是拿到 加压素 的 16 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 16 impurity entries for Vasopressin, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances